Compare Johnson & Johnson (JNJ) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Norwegian Cruise Line Holdings Ltd — how do they compare? Johnson & Johnson trades at $260.67 (market cap $618.09B), while Norwegian Cruise Line Holdings Ltd trades at $15.56 (market cap $7.11B). The key difference: Johnson & Johnson is far larger — about 86.9× Norwegian Cruise Line Holdings Ltd's market cap, and Johnson & Johnson pays a 2.09% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| JNJ | NCLH | |
|---|---|---|
Market Cap | $618.09B | $7.11B |
Volume | 6,050,983 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $25.02 |
52-Week Low | $186.00 | $14.12 |
Typical Hold Time | 129 Days | 68 Days |
Enterprise Value | $646.37B | $21.93B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
NCLH trades at $15.495, up 2.96% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.48, exceeding expectations, and anticipates Q3 2026 results above guidance. Valuation metrics appear attractive with a P/E of 9.39 and P/S of 0.75. Analyst consensus is a Buy with a $20.86 price target, indicating 34% upside potential. Recent news highlights strategic initiatives like earlier booking resets and new senior note offerings to manage debt.
The outlook for NCLH is positive, driven by earnings momentum and favorable analyst sentiment, but risks include persistent yield pressure and high debt levels. Investment opportunity lies in the stock's discounted valuation relative to growth prospects, though investors must monitor Caribbean pricing trends and the company's ability to sustain profitability amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
